SPA
MIRM icon

Sherbrooke Park Advisers’s Mirum Pharmaceuticals MIRM Stock Holding History

Sherbrooke Park Advisers’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,355
Closed -$263K – 810
2024
Q4 		$263K Sell
6,355
-424
-6% -$17.7K 0.08% 463
2024
Q3 		$264K Buy
+6,779
New +$270K 0.06% 629

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sherbrooke Park Advisers's MIRM Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Mirum Pharmaceuticals (MIRM) in Q1 2025, closing a stake of 6,355 shares — an estimated $263K sold.

Sherbrooke Park Advisers first reported a position in MIRM in Q3 2024 and held it in 2 quarters. The position peaked at $264K in Q3 2024. 214 funds tracked by Wall St. Rank hold MIRM as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Mirum Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 6,355 Mirum Pharmaceuticals shares in Q1 2025, an estimated $263K.
  • Sherbrooke Park Advisers first reported a position in Mirum Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Mirum Pharmaceuticals position peaked at $264K in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.